Statin intolerance: Reconciling clinical trials and clinical experience

JAMA - Journal of the American Medical Association

Volumn 313, Issue 10, 2015, Pages 1011-1012

  Newman, Connie B ^a   Tobert, Jonathan A ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALIROCUMAB; ATORVASTATIN; CREATINE KINASE; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

AGE DISTRIBUTION; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DRUG SAFETY; DRUG TOLERANCE; ENZYME BLOOD LEVEL; HUMAN; LIPOPROTEIN BLOOD LEVEL; MUSCLE WEAKNESS; MYALGIA; NOTE; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHABDOMYOLYSIS; RISK ASSESSMENT; TREATMENT DURATION; TREATMENT WITHDRAWAL; CHEMICALLY INDUCED; DOUBLE BLIND PROCEDURE; MUSCLE DISEASE;

DOUBLE-BLIND METHOD; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MUSCULAR DISEASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84924386462     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2015.1335     Document Type: Note

References (8)

1. Baigent C, Blackwell L, Emberson J, et al; Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: ameta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-1681.
2. Fernandez G, Spatz ES, Jablecki C, Phillips PS. Statinmyopathy: a common dilemma not reflected in clinical trials. Cleve Clin JMed. 2011;78(6):393-403.
3. Amarenco P, Bogousslavsky J, Callahan A III, et al; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355(6):549-559.
4. Maningat P, Breslow JL. Needed: pragmatic clinical trials for statin-intolerant patients. N Engl J Med. 2011;365(24):2250-2251.
5. Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel members. An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia-full report. J Clin Lipidol. 2014;8(1):29-60.
6. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7-22.
7. Zhang H, Plutzky J, Skentzos S, et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med. 2013;158(7):526-534.
8. Moriarty PM, Thompson PD, Cannon CP, et al. ODYSSEY ALTERNATIVE: efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody, alirocumab, versus ezetimibe, in patients with statin intolerance as defined by a placebo run-in and statin rechallenge arm [ClinicalTrials.gov Identifier:NCT01709513]. Presented at: American Heart Association Scientific Sessions: Late-Breaking Clinical Trials: Anti-Lipid Therapy and Prevention of CAD; Chicago, IL; November 17, 2014. http://my.americanheart.org/idc/groups/ahamah-public/@wcm/@sop/@scon/documents/downloadable/ucm-469684.pdf. Accessed November 25, 2014.